Gilead Sciences, Inc. announced that the Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival (OS) in previously treated metastatic non-small cell lung cancer (NSCLC). EVOKE-01 is evaluating Trodelvy® (sacituzumab govitecan-hziy; SG) vs. docetaxel in patients with metastatic or advanced NSCLC that had progressed on or after platinum-based chemotherapy and checkpoint inhibitor therapy.

A numerical improvement in OS favoring SG was observed in the study, including in patients with both squamous and non-squamous histology. The safety profile for Trodelvy was consistent with prior studies. Trodelvy was generally well tolerated, and no new safety signals were identified in this patient population.

A more than three-month difference in median OS favoring SG was observed in a sub-group of patients non-responsive to last prior anti-PD-(L)1 therapy, representing over 60% of the trial population. This analysis was pre-specified in the protocol, but not alpha-controlled for formal statistical testing. This magnitude of difference was not observed in the sub-group of patients with response to last prior anti-PD-(L)1 therapy.

Gilead intends to explore potential pathways to further understand the role SG may have in these patients given the high unmet medical need. Gilead plans to discuss results from this trial with regulators. The data will be presented at an upcoming medical meeting.

Gilead?s clinical development program in metastatic NSCLC is broad and includes multiple ongoing registrational Phase 3 studies and several ongoing Phase 2 studies. Based on strong preliminary efficacy and safety data from the Phase 2 EVOKE-02 study of Trodelvy in combination with pembrolizumab, presented at the World Conference on Lung Cancer 2023, Gilead remains confident in its ongoing Phase 3 EVOKE-03 study in 1L metastatic PD-L1 high NSCLC. The EVOKE-03 study is currently enrolling.

In addition, Gilead has a broad clinical development program in lung cancer with domvanalimab, the first Fc-silent investigational anti-TIGIT antibody.